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There is increasing evidence that urinary albumin excretion,
even when below the accepted threshold values for
normal excretion, may have significant impact on future
cardiovascular risks. To further define this, a total of 1086
patients, aged 45 years and older from the population-based,
longitudinal ‘Study of Health in Pomerania’ were evaluated.
Patients had echocardiographic analysis at baseline and
5-year follow-up, and were grouped into quartiles according
to their baseline urinary albumin-to-creatinine ratio. At
baseline, left ventricular mass in the first three quartiles was
similar; however, the fourth quartile was significantly
elevated and further increased over the 5-year follow-up.
In the first quartile, the albumin-to-creatinine ratio and left
ventricular mass did not significantly change over 5 years.
In the second and third quartiles, the left ventricular mass
progressively increased and was significantly correlated
with the albumin-to-creatinine ratio. In multivariable analysis,
this association was independent of other common
cardiovascular risk factors and applicable to both genders.
Our study found that the urinary albumin-to-creatinine ratio,
even below the current threshold for definition of
microalbuminuria, is significantly associated with increased
left ventricular mass.
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The development of left ventricular hypertrophy (LVH) is
significantly associated with the occurrence of adverse cardio-
vascular events, such as myocardial infarction, heart failure,
stroke, and also cardiovascular mortality.1–4 Recently, various
risk factors for LVH apart from arterial hypertension were
identified on the basis of population-based studies and
investigational trials: among others age, gender, renal function,
hematocrit, and thyroid hormone status were significantly
associated with left ventricular mass (LVM) in several
investigations.5–8 However, when considering principles of
preventive medicine, it seems to be of outstanding relevance
to identify parameters, associated with further increase of
LVM over time in a longitudinal study design, as these variables
may become a valuable basis on which preventive measures or
intensified treatment could be initiated.9
Micro- and macroalbuminuria have long been recognized
as important prognostic factors both in individuals with
and without diabetes mellitus.10–12 There is increasing
evidence that urinary albumin excretion below currently
accepted threshold values for the definition of microalbumi-
nuria (X2.5mg urinary albumin/mmol creatinine for men
and X3.5mg/mmol for women13) has also significant
prognostic impact with respect to several cardiovascular risk
factors.10,14,15 In the Heart Outcomes Prevention Evaluation
Study (HOPE), for example, rates of cardiovascular events
and mortality increased steadily with every quartile of the
urinary albumin-to-creatinine ratio (ACR).10 Interestingly,
in the first three quartiles, ACR values were far below the
definition of microalbuminuria; nonetheless, the prognostic
impact of ACR within these quartiles was striking. Further-
more, most of the studies, investigating the impact of urinary
albumin excretion, demonstrated associations independent
of common cardiovascular risk factors, which highlights
albuminuria as a potential useful parameter in preventive
cardiovascular medicine.10,12,14,16
As microalbuminuria is regarded as a sensitive indicator of
a generalized vascular process with different consequences in
various organs, we sought to investigate whether urinary
albumin excretion is associated with the development of
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LVM over time. We used data from subjects aged 45 years and
older of the population-based ‘Study of Health in Pomerania’
(SHIP) that provides a comprehensive set of echocardio-
graphic investigations at baseline and at follow-up after
5 years in combination with sociodemographic, medical and
laboratory parameters.17
RESULTS
Association of clinical characteristics, cardiovascular risk
factors and drug therapy at baseline and at 5-year follow-up
with urinary ACR
Age was significantly higher in ACR quartile IV, but similar
in the first three quartiles (Tables 1 and 2). Women tended
to have slightly higher urinary ACR than men (median:
0.90mg/mmol; female 0.99mg/mmol; male: 0.80mg/mmol),
which is reflected by the lower percentage of males in the two
quartiles with higher ACR. Quartile IV (ACR41.804mg/mmol)
differed significantly from quartile I with respect to several
cardiovascular risk factors at baseline: apart from being older,
subjects in this quartile were characterized by a higher
prevalence of hypertension and diabetes mellitus. Accord-
ingly, blood pressure (BP) values, frequency of anti-
hypertensive medication, and body mass index (BMI) and
glycated hemoglobin levels were also significantly higher.
No significant differences were found between quartile I and
II, whereas quartile III showed slightly higher BP values
compared with quartile I and II. It is interesting that renal
function at baseline was similar in the four quartiles; only
after five years estimated glomerular filtration rate was
significantly lower in quartile IV. Non-parametric correlation
analysis (Spearman) revealed a significant positive correlation
between urinary ACR and systolic (r¼ 0.220, Po0.001),
diastolic BP (r¼ 0.104, Po0.001), pulse pressure (r¼ 0.239,
Po0.001), glycated hemoglobin (r¼ 0.105, Po0.001) and
BMI (r¼ 0.129, Po0.001) at baseline, but not with estimates
of renal function and cholesterol levels. Antihypertensive
treatment was similar in frequency in quartile I and II, but
higher in quartile IV.
Echocardiographic variables at baseline and after 5 years in
relation to the urinary ACR
At baseline, parameters of LVM assessed by echocardiography
were very similar in the three lowest quartiles of urinary ACR
(Figure 1). However, individuals in the highest ACR quartiles
(41.804mg/mmol) were characterized by significantly higher
LVM and LVM indices at baseline (Table 3). For the entire
population, LVM increased from 187.6±1.7 g at baseline
to 197.6±1.8 g over 5 years (females (n¼ 590): 164.2±1.8
to 174.7±2.1 g; males (n¼ 496): 215.5±2.5 g at baseline to
224.9±2.6 g after 5 years) with a mean intra-individual
Table 1 | Clinical characteristics, laboratory parameters and drug therapy at baseline in relation to urinary
albumin-to-creatinine ratio at baseline
Urinary albumin-to-creatinine ratio (mg/mmol) at baseline (quartiles)
Statistics (ANOVA
or v2 test
between quartiles)
Entire
population
Baseline
I 0–0.532
(n=272)
II 40.532–0.902
(n=271)
III 40.902–1.804
(n=272)
IV 41.804
(n=271) P-value (n=1086)
Age (years) 57.8±0.5(IV) 58.0±0.5 59.7±0.5 62.3±0.6(I, II, III) 0.001 59.4±0.3
Sex (%, male) 49.6 50.2 40.4 42.4 0.044 45.7
Arterial hypertension (%) 53.3 56.8 66.2 81.2 0.001 64.4
Diabetes mellitus (%) 7.0 5.2 11.4 15.9 0.001 9.9
Cigarette smoker (%) 22.4 17.4 21.3 17.4 n.s. 19.6
Previous MI (%) 3.7 4.8 3.3 4.8 n.s. 4.2
Systolic BP (mmHg) 137.6±1.2(III, IV) 138.4±1.1(IV) 142.4±1.2(I, IV) 151.0±1.4(I, II, III) 0.001 142.4±0.6
Diastolic BP (mmHg) 84.8±0.7(IV) 85.0±0.6(IV) 86.0±0.7(IV) 88.5±0.7(I, II, III) 0.001 86.1±0.3
Pulse pressure (mmHg) 52.8±0.9(III, IV) 53.4±0.8(IV) 56.4±0.9(I, IV) 62.5±1.0(I, II, III) 0.001 56.3±0.5
LDL cholesterol (mmol/l) 3.88±0.07 3.92±0.07 3.74±0.06 3.87±0.08 n.s. 3.85±0.04
HB A1c (%) 5.51±0.05(IV) 5.53±0.05(IV) 5.61±0.06(IV) 5.91±0.08(I, II, III) 0.001 5.64±0.03
BMI (kg/m2) 27.3±0.3(IV) 27.7±0.2 28.1±0.3 28.6±0.3(I) 0.004 27.9±0.1
CCl (ml/min per 1.73 m2) 78.3±0.9 80.1±0.9 78.9±1.0 76.3±1.1 n.s. 78.4±0.5
eGFRMDRD (ml/min per 1.73m
2) 74.5±0.8 76.1±0.8 74.8±0.7 73.5±0.8 n.s. 74.7±0.4
Antihypertensive drugs (%) 32.7 32.1 40.1 55.7 0.001 40.1
Diuretics (%) 9.6 5.5 11.4 16.2 0.001 10.7
b-Blocker (%) 18.0 18.5 19.1 23.6 n.s. 19.8
Calcium antagonist (%) 9.9 9.2 13.6 26.2 0.001 14.7
ACE-inhibitor (%) 13.6 11.1 16.9 28.4 0.001 17.4
Angiotensin-II-antagonist (%) 0.4 3.3 2.9 3.0 n.s. 2.4
Abbreviations: ACE, angiotensin converting enzyme; ANOVA, analysis of variance; BMI, body mass index; BP, blood pressure; CCl, estimated creatinine clearance (Cockcroft
Gault); eGFRMDRD estimated glomerular filtration rate (MDRD-formula); HB A1c, glycated hemoglobin; LDL, low density lipoprotein; MI, myocardial infarction; n.s., not
significant.
Mean±s.e.m. for continuous variables, % for frequency data. Statistics: P-value for w2 test (numerical data) or one-way-ANOVA (continuous data) with Tukey’s post hoc test for
comparisons between quartiles (groups with significant differences according to Tukey’s post hoc testing in superscript roman).
1116 Kidney International (2010) 77, 1115–1122
or ig ina l a r t i c l e T Reffelmann et al.: Urinary albumin excretion and left ventricular mass
difference in LVM (DLVM) of 10.0±1.4 g (females: 10.5±1.8 g;
males: 9.3±2.3 g).
In individuals, presenting with a urinary ACR of
p0.532mg/mmol (lowest quartile), LVM did not signifi-
cantly increase over 5 years (þ 0.2±2.7 g), whereas indivi-
duals in the other three quartiles demonstrated a substantial
gain in LVM (Table 3): in women, LVM increased by
þ 0.9±3.2 g in quartile I, but by þ 13.6±3.1 g, þ 14.6±3.4 g,
and þ 12.0±4.2 g in quartile II–IV, respectively. In men, the
difference in LVM over 5 years in quartile I was 0.6±4.3 g,
but þ 9.5±4.2 g, þ 13.8±5.1 g, and þ 16.5±5.1 g in quartiles
II–IV, respectively.
After 5 years, LVM and indices of LVM in both gender
subgroups and the entire population were significantly higher
in the three quartiles with higher ACR in comparison with
quartile I (Table 3).
DLVM correlated significantly with urinary ACR at
baseline in the entire population (Po0.001), and also in
the female (Po0.016) and the male subgroup (Po0.016).
When subjects with baseline urinary ACR above the gender-
specific upper reference limits for the definition of micro-
albuminuria (females: X3.5mg/mmol; males: X2.5mg/mmol
ACR13) were excluded from the correlation analysis, again,
there was a statistically significant correlation between baseline
ACR and DLVM in individuals with very low albumin
excretion (females: r¼ 0.107, Po0.017, n¼ 501; males:
r¼ 0.105, Po0.033, n¼ 411).
Table 2 | Clinical characteristics, laboratory parameters and drug therapy after 5 years in relation to urinary
albumin-to-creatinine ratio at baseline
Urinary albumin-to-creatinine ratio (mg/mmol) at baseline (quartiles)
Statistics (ANOVA
or v2 test
between quartiles)
Entire
population
After 5 years
I 0–0.532
(n=272)
II 40.532–0.902
(n=271)
III 40.902–1.804
(n=272)
IV 41.804
(n=271) P-value (n=1086)
Arterial hypertension (%) 52.2 63.1 71.3 83.4 0.001 67.5
Diabetes mellitus (%) 10.7 8.9 14.4 21.3 0.001 13.8
Cigarette smoker (%) 17.3 14.0 18.1 14.9 n.s. 16.1
Previous MI (%) 4.4 7.0 5.9 7.0 n.s. 6.1
Systolic BP (mmHg) 133.2±1.1(III, IV) 135.3±1.0(IV) 139.1±1.2(I) 142.3±1.3(I, II,) 0.001 137.5±0.6
Diastolic BP (mmHg) 81.0±0.6 81.9±0.6 82.4±0.6 81.7±0.7 n.s. 81.8±0.3
Pulse pressure (mmHg) 52.2±0.8(III, IV) 53.4±0.8(III, IV) 56.7±0.9(I,II, IV) 60.6±1.0(I, II, III) 0.001 55.7±0.5
LDL cholesterol (mmol/l) 3.79±0.06(IV) 3.72±0.06 3.71±0.05 3.54±0.06(I) 0.022 3.69±0.03
HB A1c (%) 5.61±0.05(IV) 5.60±0.05(IV) 5.71±0.06(IV) 5.92±0.06(I, II, III) 0.001 5.71±0.03
BMI (kg/m2) 27.8±0.3(IV) 28.2±0.3 28.8±0.3 28.9±0.3(I) 0.019 28.4±0.1
CCl (ml/min per 1.73 m2) 79.0±1.2(IV) 81.8±1.2(IV) 78.9±1.2(IV) 73.6±1.4(I, II, III) 0.001 78.3±0.6
eGFRMDRD (ml/min per 1.73m
2) 76.4±1.1(IV) 78.9±1.0(IV) 76.0±1.1(IV) 71.5±1.2(I, II, III) 0.001 75.7±0.6
Antihypertensive drugs (%) 29.4 33.9 34.2 50.6 0.001 37.0
Diuretics (%) 10.3 7.7 12.9 21.8 0.001 13.2
b-Blocker (%) 18.8 21.8 19.9 29.9 0.008 22.6
Calcium antagonist (%) 7.0 5.5 7.0 15.9 0.001 8.8
ACE inhibitor (%) 15.8 13.7 15.8 32.1 0.001 19.3
Angiotensin-II-antagonist (%) 1.5 5.9 7.0 7.0 0.011 5.3
Abbreviations: ACE, angiotensin converting enzyme; ANOVA, analysis of variance; BMI, body mass index; BP, blood pressure; CCl, estimated creatinine clearance (Cockcroft
Gault); eGFRMDRD estimated glomerular filtration rate (MDRD-formula); HB A1c, glycated hemoglobin, LDL, low density lipoprotein; MI, myocardial infarction; n.s., not
significant.
Mean±s.e.m. for continuous variables, % for frequency data. Statistics: P-value for w2 test (numerical data) or one-way-ANOVA (continuous data) with Tukey’s post hoc test for
comparisons between quartiles (groups with significant differences according to Tukey’s post hoc testing in superscript roman).
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Figure 1 | Left ventricular mass and urinary albumin-to-creatinine
ratio. Top: Difference in left ventricular mass (LVM) over 5 years in
relationship to urinary albumin-to-creatinine ratio (ACR) at baseline
in subjects with complete echocardiographic data and data on urinary
ACR ratio (circles and lines: scatter plot and polynomal regression
lines (7th order) of DLVM versus ACR (r¼ 0.13) with 95% confidence
interval). Bottom: LVM at baseline and after 5 years in relationship
to ACR at baseline in subjects with complete echocardiographic data
and data on urinary ACR (circles and lines: scatter plot and polynomal
regression lines (7th order) of LVM at baseline (r¼ 0.16) and LVM after
5 years (r¼ 0.19) versus ACR with 95% confidence interval, respectively).
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Association of urinary ACR with the DLVM over 5 years after
multivariable adjustment
By multivariable analysis (Table 4), the association between
ACR (log2) and DLVM remained highly significant. Four
different models with increasing number of potential
confounders were applied (see Materials and Methods).
The LVM value at the baseline was inversely correlated with
DLVM (r¼0.319, Po0.001). When LVM after 5 years
instead of DLVM was included as the dependent variable into
the models, results were similar (model 3: b-coefficient (s.e.)
for ACR (log2): 2.435 (0.459), P¼ 0.001). Results were also
similar after including LVM at baseline as an additional
confounder into this model (model 3: b-coefficient (s.e.) for
ACR (log2): 2.422 (0.404), P¼ 0.001; b-coefficient (s.e.) for
LVM at baseline: 0.526 (0.030), P¼ 0.001). In a separate
analysis (model 4), various parameters determined at the
5-year follow-up were included as potential confounders and
covariates. Here again the association between ACR at
baseline (log2) and change in LVM was highly significant
(b-coefficient (s.e.) for ACR: 2.314 (0.446), P¼ 0.001).
Stratified analyses
Various subgroups stratified according to gender, parameters
of arterial hypertension and antihypertensive treatment, and
other parameters were analyzed separately: in the fully
adjusted model (model 3) the association between urinary
ACR (log2) and DLVM remained statistically significant in
the female subgroup (n¼ 581, b-coefficient (s.e.) for ACR:
2.172 (0.522), P¼ 0.001) and in the male subgroup (n¼ 495,
b-coefficient (s.e.) for ACR: 2.814 (0.783), P¼ 0.001). Similarly,
the association between urinary ACR (log2) and DLVM was
significant in subjects with arterial hypertension (n¼ 692,
b-coefficient (s.e.) for ACR: 2.897 (0.582), P¼ 0.001), and
subjects without arterial hypertension (n¼ 384, b-coefficient
(s.e.) for ACR: 1.567 (0.700), P¼ 0.026). Further analyses
stratified by systolic blood pressure 4140mmHg versus
o¼ 140mmHg; diastolic blood pressure 490mmHg versus
o¼ 90mmHg; and subjects on antihypertensive medical
treatment and subjects without antihypertensive treatment
revealed similar results.
Furthermore, the association between ACR and DLVM
was statistically significant in individuals without previous
myocardial infarction (n¼ 1031, b-coefficient (s.e.) for ACR:
2.449 (0.451), P¼ 0.001), and in subjects without diabetes
mellitus (n¼ 969, b-coefficient (s.e.) for ACR: 2.317 (0.468),
P¼ 0.001). There was only a nonsignificant trend in subjects
with diabetes mellitus (n¼ 107, b-coefficient (s.e.) for ACR:
3.452 (1.749), P¼ 0.051).
Representativeness of the data
In the entire baseline sample, restricted to subjects aged
45 years or older (n¼ 2619, age: 61.4±0.2 years, 50.7%
males), prevalence of arterial hypertension was 69.1% and
prevalence of diabetes mellitus was 12.6%. Measured BP
values at baseline averaged 144.3±0.4mmHg for systolic
BP and 86.0±0.2mmHg for diastolic BP. Median urinary
ACR (n¼ 2193) was 1.020mg/mmol, LDL cholesterol was
3.83±0.04mmol/l and glycated hemoglobin was 5.71%. The
LVM value at baseline amounted to 191.6±1.3 (n¼ 1951)
and LVM after 5 year was 201.0±1.6 (n¼ 1667). In subjects
Table 3 | Echocardiographic data at baseline and 5-year follow-up in relation to urinary albumin-to-creatinine ratio at baseline
Urinary albumin-to-creatinine ratio (mg/mmol) at baseline (quartiles)
Statistics (ANOVA
or v2 test
between quartiles)
Entire
population
I 0–0.532
(n=272)
II 40.532-0.902
(n=271)
III 40.902-1.804
(n=272)
IV 41.804
(n=271) P-value (n=1086)
Baseline
LVd (mm) 51.1±0.3 51.6±0.3 50.6±0.4 51.0±0.4 n.s. 51.1±0.2
SWd (mm) 9.6±0.1(IV) 9.7±0.2(IV) 9.7±0.1(IV) 10.4±0.1(I, II, III) 0.001 9.9±0.1
PWd (mm) 9.7±0.1 9.6±0.1(IV) 9.8±0.1 10.1±0.1(II) 0.028 9.8±0.1
LVM (g) 182.8±3.3(IV) 186.8±3.4 182.9±3.3(IV) 198.1±3.6(I, III) 0.004 187.6±1.7
LVMIBSA (g/m
2) 97.6±1.5(IV) 99.2±1.6(IV) 98.4±1.5(IV) 105.8±1.6(I, II, III) 0.001 100.2±0.8
LVMIht(g/m
2.7) 45.1±0.8(IV) 46.2±0.8(IV) 46.7±0.8(IV) 50.7±0.9(I, II, III) 0.001 47.2±0.4
FS (%) 38.0±0.4 38.2±0.5 36.9±0.5 37.9±0.5 n.s. 37.8±0.2
After 5 years
LVd (mm) 48.8±0.3 48.9±0.3 48.8±0.3 49.7±0.4 n.s. 49.1±0.2
SWd (mm) 10.7±0.2(II, III, IV) 11.6±0.2(I) 11.4±0.2(I) 11.9±0.2(I) 0.001 11.4±0.1
PWd (mm) 9.7±0.1(III, IV) 10.0±0.1 10.1±0.1(I) 10.4±0.1(I) 0.001 10.1±0.1
LVM (g) 183.0±3.3(II, III, IV) 198.3±3.5(I, IV) 197.2±3.5(I, IV) 211.9±3.9(I, II, III) 0.001 197.6±1.8
LVMIBSA (g/m
2) 97.5±1.5(II, III, IV) 104.7±1.6(I, IV) 105.8±1.6(I, IV) 113.4±1.8(I, II, III) 0.001 105.3±0.8
LVMIht (g/m
2.7) 45.5±0.8(II, III, IV) 49.1±0.8(I, IV) 50.9±0.9(I, IV) 54.6±1.0(I, II, III) 0.001 50.0±0.4
FS (%) 38.2±0.5 38.4±0.5 38.4±0.5 38.9±0.6 n.s. 38.5±0.3
Comparison of baseline and
follow-up
D LVM (5 years) (g) 0.2±2.7(II, III, IV) 11.5±2.6(I) 14.3±2.9(I) 13.9±3.2(I) 0.001 10.0±1.4
Abbreviations: D, difference; ANOVA, analysis of variance; BSA, body surface area; FS, fractional shortening; LVd, diastolic left ventricular diameter; LVM, left ventricular mass;
LVMIBSA, left ventricular mass indexed by body surface area; LVMIht, left ventricular mass indexed by height
2.7; PWd, diastolic thickness of the posterior wall; SWd, diastolic
thickness of the interventricular septum; n.s., not significant.
Mean±s.e.m. Statistics: P-value for one-way ANOVA (continuous data) with Tukey’s post hoc test for comparisons between quartiles (groups with significant differences
according to Tukey’s post hoc testing in superscript roman).
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with complete data for ACR and LVM at baseline (n¼ 1616),
median ACR was 0.962mg/mmol and baseline LVM was
193.0±1.4 (n¼ 1616), whereas LVM after 5 years in this
subgroup was 197.9±1.8 g (n¼ 1102). Thus, in comparison
with individuals with complete data, as shown in Tables 1
and 2, no obvious trend toward a different profile of
cardiovascular risk was apparent in the entire population
aged 45 years and older, even if representativeness might be
limited to a certain extent.
DISCUSSION
The present analysis demonstrates a significant association
of urinary ACR at baseline with increase in LVM over the
following 5 years in a population-based sample of individuals
aged 45 years and older. Multivariable analysis identified
ACR as being independently associated with increase in
LVM over 5 years among various cardiovascular risk
factors. Interestingly, ACR values well below the currently
recommended limits for definition of microalbuminuria
were significantly associated with increase in LVM; only
the lowest quartile (ACR: 0–0.532) in this population did
not show significant increase in LVM over 5 years.
Prognostic value of urinary albumin excretion and LVH
There is increasing evidence from several clinical trials and
epidemiological studies that urinary albumin excretion is
significantly associated with cardiovascular events and
mortality both in diabetics and nondiabetic patients.10,11,12
Furthermore, LVH, as assessed by echocardiography and
by electrocardiography, was identified as a highly valuable
predictor of cardiovascular events, including myocardial
infarction, cerebrovascular events, and cardiovascular mor-
tality.1–4 Importantly, regression of LVM during treatment
was shown to be associated with a reduction of cardiovas-
cular risk, as demonstrated in the Losartan Intervention
For Endpoint Reduction study (LIFE) with 4.8 years of
follow-up in patients with baseline LVH.2 Therefore, the
‘modifiable risk factor’ LVM could become an attractive
target in preventive medicine; and validation of factors
associated with the development of LVM over time seems to
be imperative.
In the large-scale Prevention of Renal and Vascular End
Stage Disease (PREVEND) study, 40,548 individuals of the
city of Groningen (The Netherlands) were analyzed with
respect to cardiovascular and non-cardiovascular mortality
over a median follow-up of 961 days in relation to urinary
albumin concentration measured in a morning sample at
baseline:18 Both cardiovascular and non-cardiovascular deaths
were more common in individuals with higher urinary
albumin excretion even after adjustment for multiple risk
factors as assessed by a brief questionnaire at baseline. The
Third Copenhagen Heart Study emphasized that even very
low levels of urinary albumin excretion were associated with
incident coronary heart disease and mortality independent
of age, gender, renal function, diabetes mellitus, and arterial
hypertension.19
An analysis of the LIFE echocardiographic sub-study
demonstrated that cardiovascular events were associated
with urinary albumin excretion independently of LVM at
baseline, suggesting supplemental prognostic information of
both variables.20 Comparison of echocardiographical LVM
with BP values and somatometric data, as investigated in 402
consecutive untreated hypertensive patients from an outpatient
clinic in Italy, showed that urinary ACR was associated with
inappropriately high values of LVM as estimated on the
basis of gender, height, and calculated hemodynamic stroke
work.21
However, there is no scientific data on the development
of LVM over time in relation to urinary ACR at baseline.
Table 4 | Coefficients, s.e. values, and P-values for the
relationship between urinary albumin-to-creatinine ratio and
other potential risk factors of left ventricular hypertrophy
and change in left ventricular mass over 5 years (DLVM), as
analyzed by general linear model (see Materials and
Methods)
DLVM (g)
b (s.e.) P-value
Unadjusted model
Albumin-to-creatinine ratio (log2) 2.176 (0.438) 0.001
Model 1 (multiple r2=0.020)
Albumin-to-creatinine ratio (log2) 2.225 (0.440) 0.001
Gender (male=1; female=2) 1.056 (2.853) 0.711
Age/10 (quadratic; years) 0.174 (1.758) 0.921
Age/10 (linear; years) 4.050 (21.541) 0.851
Model 2 (multiple r2=0.031)
Albumin-to-creatinine ratio (log2) 2.457 (0.444) 0.001
Gender (male=1; female=2) 0.898 (2.899) 0.757
Age/10 (quadratic; years) 0.339 (1.761) 0.847
Age/10 (linear; years) 3.064 (21.551) 0.887
Arterial hypertension 2.857 (3.569) 0.423
Pulse pressure (mmHg) 0.260 (0.125) 0.038
HB A1c (%) 2.938 (1.523) 0.054
Model 3 (multiple r2=0.046)
Albumin-to-creatinine ratio (log2) 2.411 (0.450) 0.001
Gender (male=1; female=2) 0.471 (2.983) 0.874
Age/10 (quadratic; years) 0.440 (1.775) 0.872
Age/10 (linear; years) 3.512 (21.73) 0.804
Arterial hypertension 1.456 (3.788) 0.701
Diabetes mellitus 4.533 (21.642) 0.834
Pulse pressure (mmHg) 0.303 (0.129) 0.019
HB A1c (%) 3.540 (1.794) 0.049
BMI (kg/m2) 0.415 (0.410) 0.312
CCl (ml/min per 1.73 m2) 0.084 (0.246) 0.732
Smoking status 1.445 (3.792) 0.703
Use of diuretics (y/n) 1.522 (5.419) 0.779
Use of b-blockers (y/n) 5.127 (3.749) 0.172
Use of Ca2+ antagonists (y/n) 4.348 (4.434) 0.327
Use of ACE inhibitors (y/n) 5.720 (4.404) 0.194
Use of AT-II antagonists (y/n) 13.034 (9.746) 0.181
Abbreviations: ACE, angiotensin converting enzyme; AT, angiotensin; BMI, body mass
index; CCl, estimated creatinine clearance (per 1.73m2 body surface area); HB A1c,
glycated hemoglobin; LVM, left ventricular mass; n.s., not significant.
Albumin-to-creatinine ratio (logs), ACR after logarithmic transformation (log2: logarithm
to the basis 2, therefore the coefficient illustrates the average DLVM associated with
doubling of ACR). Age was included after division by 10 (therefore the coefficient
illustrates the average DLVM associated with an increase of 10 years of age).
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This study is, to the best of our knowledge, the first to
demonstrate that urinary albumin excretion is associated
with increase in LVM over the following 5 years in a
population-based cohort as analyzed on a longitudinal
basis. This association may provide a link between the
prognostic value of urinary ACR, the prognostic value of
LVH, and the incidence of cardiovascular events over time.
Even if the exact pathophysiological steps linking urinary
ACR with the development of LVM over time remain to
be evaluated, a generalized vascular process, including
endothelial dysfunction and increased microvascular
permeability, but also activation of the renin–angiotension–
aldosterone system or sympathetic nervous activation can be
discussed.22
Association of urinary albumin excretion with cardiovascular
risk factors
Apart from a significantly higher cardiovascular risk profile
in quartile IV, urinary ACR showed only weak associations
with most markers of cardiovascular risk in the other
quartiles (Tables 1 and 2). Prevalence of arterial hypertension
in quartile I did not change over time (52.2–53.3%); however,
there was a notable increase in prevalent hypertension in
quartile II and III, and to some extent even in quartile IV.
Indeed, albuminuria in normotensive subjects is also
significantly associated with the development of arterial
hypertension over the following years:23,24 in a study
including more than 2000 women without diabetes mellitus
or hypertension at baseline, incident arterial hypertension
over a maximum of 8 years of follow-up was significantly
predicted by urinary ACR at baseline.23
In this analysis, development of other risk factors
over 5 years was similar in the four quartiles save some
increase in prevalent diabetes mellitus, decrease in LDL
cholesterol, and a significant reduction in estimated creati-
nine clearance in quartile IV. Notably, changes in BMI,
glycated hemoglobin levels, and various fractions of serum-
cholesterol over time were similar in quartiles I–III.
Comparison of BP values at baseline and after 5 years did
not demonstrate a consistent trend within quartiles II and III
that could directly explain the pronounced increase in LVM
in these groups. Therefore, the higher increase in LVM in
quartiles II and III may, in part, be related to the increasing
prevalence of hypertension over time in these quartiles;
however, it could not be directly related to cardiovascular risk
factors or BP values.
Multivariable analysis demonstrated that urinary ACR was
associated with increase in LVM independently of age and
gender, but also independently of various confounding factors
at baseline and at 5-year follow-up, including prevalent
hypertension and BP values at a high significance level.
Systematic stratified analyses, investigating the interrelation
between arterial hypertension, antihypertensive treatment
and measured blood pressure values revealed significant
associations of ACR with DLVM over time in any of the
subgroups, which again confirms that urinary ACR adds
supplemental information to various established risk factors,
including arterial hypertension for the identification of
subjects at risk for developing LVH. Nonetheless, as BP
values in this study were measured only at baseline and after
5 years, which may not reflect complete hemodynamic
burden over time, there might be still some residual
confounding by arterial BP. Notably, the magnitude of the
observed associations between urinary ACR and DLVM
differs to some extent in the subgroups with and without
prevalent arterial hypertension, which may also point into
this direction.
Limitations
The associations between urinary ACR and changes in LVM
in this analysis are evaluated from a population-based cohort,
which reflects, with limitations, real world conditions,
including the specific sociodemographic, environmental,
and genetic background including availability and utilization
of medical care. Owing to a number of individuals
without echocardiographic readings sufficient for valuable
calculation of LVM and some subjects with missing urinary
ACR values mainly due to technical and organizational
issues and, of course, the incomplete response, the repre-
sentativeness of the associations found in this analysis is
limited to a certain extent. However, comparison of several
variables between subjects with complete data and the
entire population restricted to individuals aged 45 years
and older revealed a similar risk profile, suggesting that
these associations are transferable to the entire cohort
on a fair basis. Moreover, urinary albumin excretion was
measured once and it was not determined over a standar-
dized sampling period as this was not realistic for the specific
conditions of a population-based study. Therefore, to
account for different urine concentration, division by urinary
creatinine concentrations was used, which is regarded as a
valuable estimate.25
Perspective
According to the associations found in this analysis, urinary
ACR higher than approximately 0.5mg/mmol may identify
subjects prone to marked increase in LVM over the following
years. Further studies are warranted to clarify whether
subjects with higher urinary ACR benefit from close
monitoring of LVM over time and intensified preventive or
therapeutic measures.
MATERIALS AND METHODS
Study population at baseline and 5-year follow-up exclusions
The SHIP study is an epidemiological investigation referring to
212,157 inhabitants residing in a defined region of West Pomerania
(Germany).17 For the baseline examinations (1997–2001), a sample
of 6267 eligible subjects aged 20–79 years was drawn. The SHIP
population finally comprised 4310 participants (response 68.8%).
Individuals aged 45 years and older (n¼ 2619) were scheduled for
echocardiography. Between 2002 and 2006, all participants were
re-invited for an examination follow-up, of which 3300 subjects
(83.5% of eligible persons) took part. The study is reviewed by an
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external scientific review board. All participants gave informed
written consent. The study protocols are consistent with the principles
of the Declaration of Helsinki and were approved by the Ethics
Committee of the University of Greifswald.
After exclusion of 11 individuals with prosthetic heart valves,
26 with aortic stenosis, 1 subject after cardiac transplantation, 1348
individuals with echocardiographic image quality sufficient for
determination of LVM at baseline and at the 5-year follow-up visit
were available. After additional exclusion of subjects with missing
data on urinary albumin or creatinine concentration (n¼ 262, 15
individuals with positive urinary dip stick for nitrite), 1086
individuals with complete data were divided into four quartiles
according to baseline ACR for this analysis.
Data collection, echocardiography, and calculations
Medical histories and sociodemographic data were assessed by
computer-assisted personal interviews, medication was classified
using ATC (Anatomical Therapeutic Chemical Classification
System) code (for details, see John et al.17). Laboratory values
were analyzed in a central laboratory. Particularly, a single urine
sample was collected from each subject (spot urine). Urinary
albumin excretion and creatinine concentration were measured
once from samples, stored for a maximum time of 2 days at 61C.
The urinary albumin concentration was determined on a Behring
Nephelometer (Siemens BN albumin; Siemens Healthcare, Mar-
burg, Germany). The creatinine concentration (Jaffe´ method) was
determined on a Hitachi 717 (Roche Diagnostics, Germany). Day-
to-day coefficient of variation for the albumin method is p8%,
for creatinine it is p7%.
All examinations were performed by trained and certified
personnel: BP values are the mean of three measurements (at least
3min apart) in the seated position after a resting period of 5min
minimum (HEM705CP system, OMRON Healthcare, Vernon Hill,
IL, USA). The BMI value (kg/m2; weight/height2) and body surface
area (BSA; m2; BSA¼ 0.007184 height [cm]0.725weight [kg]0.425)
were calculated. Arterial hypertension was defined as a systolic BP of
X140mmHg, a diastolic BP of X90mmHg, or use of antihyper-
tensive medication. Pulse pressure was defined as the difference
between systolic and diastolic BP. Creatinine clearance was estimated
using the Cockcroft Gault formula: creatinine clearance (ml/min;
(1.00 for males, 0.85 for females) (140–age (years))weight (kg)/
(serum creatinine (mg/dl) 72)), and normalized to 1.73m2
BSA).26 Glomerular filtration rate (GFR) was estimated according
to the modified MDRD formula (GFR (ml/min/1.73m2) (186
serum creatinine1.154 age0.203 (1 for males and 0.742 for
females))).27 Echocardiographic (Vingmed CFM 800A, GE Medical
Systems Waukesha, WI, USA) readings, including standardized
M-mode recordings, were used for calculation of LVM and fractional
shortening (M-mode readings) according to published recommen-
dations.28 Indexation was performed by dividing by BSA (LVM
index: LVMIBSA) and by dividing by height
2.7 (LVMIht).
5
Statistical analyses
Continuous data are expressed as mean±s.e.m., nominal data as
absolute numbers or percentage values. Correlation analyses were
performed using Spearman’s correlation coefficient. Individuals
with complete data were divided into quartiles according to
urinary ACR. Groups were compared by w2 testing (nominal data)
or one-way analysis of variance (continuous data) with Tukey’s
post hoc test. General linear model was used for multivariable
analyses after logarithmic transformation of urinary ACR (log2).
Logarithm to the basis 2 was chosen as thereby the calculated
coefficients on average present the amount of change in LVM over
time associated with doubling urinary ACR. Age was included as a
quadratic and linear term after division by 10 years (therefore the
calculated coefficients present the amount of change in LVM
associated with 10-year increase of age; SPSS software 12.01/16.0,
SSPS, Chicago, IL, USA): the unadjusted model included only
ACR; in model 1, age and gender were added; for model 2 pulse
pressure, presence of arterial hypertension, and glycated hemo-
globin were added; for model 3, BMI, presence of diabetes
mellitus, creatinine clearance, glycated hemoglobin, smoking
status, use of diuretics, b-blockers, Ca2þ antagonists, angioten-
sin-converting enzyme inhibitors and angiotensin-II receptor
antagonists at the baseline visit, respectively, were additionally
included. Moreover, in model 4 pulse pressure, presence of arterial
hypertension, BMI, presence of diabetes mellitus, creatinine
clearance, glycated hemoglobin, smoking status, use of diuretics,
b-blockers, Ca2þ antagonists, angiotensin-converting enzyme
inhibitors and angiotensin-II receptor antagonists at 5-year
follow-up visit were included in addition to age and gender.
Stratified analyses were performed in the following subgroups:
both gender subgroups, subjects with arterial hypertension
and without arterial hypertension, systolic BP 4140mmHg
and p140mmHg, diastolic BP 490mmHg and p90mmHg,
subjects on antihypertensive treatment or without antihyperten-
sive drugs at baseline, subjects with and without diabetes mellitus,
and in subjects without previous myocardial infarction. A P-value
of o0.05 was considered statistically significant.
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